Clinical Trial Update: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update notes evaluation of siltuximab for treating cytokine release syndrome (CRS) and ICANS related to CAR-T cell therapy; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Cytokine Release Syndrome
• Immune Effector Cell Associated Neurotoxicity Syndrome
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Cytokine Release Syndrome, ICANS | Phase 2 | Status: ACTIVE_NOT_RECRUITING